Search - tctmd.com

Displaying 101 - 120 of 225

Sort: Relevancy | Date

News Industry News

4C Medical's Mitral Regurgitation Therapy to be Featured in 2017 TVT Innovation Forum

June 08, 2017

News Daily News

Updated PARTNER 2 Valve-in-Valve Registry: More Experience, Better Outcomes

Shelley Wood

May 02, 2017

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Todd Neale

March 17, 2017

News Industry News

Cardiac Dimensions Announces Investigational Device Exemption Approval from FDA to Conduct U.S. Pivotal Study of the Carillon Mitral Contour System for Functional Mitral Regurgitation

December 01, 2016

News Conference News AHA 2016

Stark Mortality Differences Seen in GARY Registry Tracking TAVR and Surgical Replacement

Shelley Wood

November 14, 2016

News Conference News TCT 2016

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

Shelley Wood

November 07, 2016

News Conference News

Watchman, Amulet LAA Closure Devices Carry Low Complication Rates

Todd Neale

November 04, 2016

News Conference News TCT 2016

TCT Mock Election: And the Winner Is...

Shelley Wood

November 02, 2016

News Opinion Editor's Corner TCT 2016

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Shelley Wood

October 24, 2016

News Conference News PCR London Valves 2016

TAVR vs SAVR: Limitations and Risks Debated as Transcatheter Therapies Move Into Younger and Lower-Risk Patients

Shelley Wood

September 20, 2016

News Conference News TVT 2016

When Is Sick Too Sick for TAVR? Physicians Grapple With Identifying Futile Care

Michael O'Riordan

June 20, 2016

News Conference News TVT 2016

Teenage TAVR: Should Practice Forge on While Guidelines Grow Up?

Michael O'Riordan

June 20, 2016

News Conference News TVT 2016

What TAVR Needs Next . . . and What It’s Getting

Shelley Wood

June 17, 2016

News Conference News ACC 2016

Sapien 3 Superior to Surgery Among Intermediate-Risk Patients in Observational Trial

Yael L. Maxwell

April 03, 2016

News Conference News ACC 2016

TAVR With Sapien XT Noninferior to Surgery in Intermediate-Risk Patients, With a Win for Transfemoral

Shelley Wood

April 02, 2016

News Features

Where Theory Meets Practice: Getting to the Heart of the Heart Team

Yael L. Maxwell

March 30, 2016

News Daily News

Patrick Whitlow, ‘Giant of Interventional Cardiology,’ Dies at 65

Yael L. Maxwell

March 22, 2016

News Conference News TCT 2015

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Yael L. Maxwell

October 15, 2015

News Conference News TCT 2015

TCT Remembers Liliana Grinfeld, MD, PhD

October 14, 2015

News Conference News TCT 2015

Boston Scientific Co-founder John Abele Recognized by TCT Career Achievement Award

October 12, 2015

Advertisement

4C Medical's Mitral Regurgitation Therapy to be Featured in 2017 TVT Innovation Forum

Updated PARTNER 2 Valve-in-Valve Registry: More Experience, Better Outcomes

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Cardiac Dimensions Announces Investigational Device Exemption Approval from FDA to Conduct U.S. Pivotal Study of the Carillon Mitral Contour System for Functional Mitral Regurgitation

Stark Mortality Differences Seen in GARY Registry Tracking TAVR and Surgical Replacement

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

Watchman, Amulet LAA Closure Devices Carry Low Complication Rates

TCT Mock Election: And the Winner Is...

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

TAVR vs SAVR: Limitations and Risks Debated as Transcatheter Therapies Move Into Younger and Lower-Risk Patients

When Is Sick Too Sick for TAVR? Physicians Grapple With Identifying Futile Care

Teenage TAVR: Should Practice Forge on While Guidelines Grow Up?

What TAVR Needs Next . . . and What It’s Getting

Sapien 3 Superior to Surgery Among Intermediate-Risk Patients in Observational Trial

TAVR With Sapien XT Noninferior to Surgery in Intermediate-Risk Patients, With a Win for Transfemoral

Where Theory Meets Practice: Getting to the Heart of the Heart Team

Patrick Whitlow, ‘Giant of Interventional Cardiology,’ Dies at 65

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

TCT Remembers Liliana Grinfeld, MD, PhD

Boston Scientific Co-founder John Abele Recognized by TCT Career Achievement Award

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content